Cancer Vaccines
Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL
Published in Medical Letter on the CDC and FDA, July 8th, 2007
Merck & Co., Inc. announced that the Food and Drug Administration (FDA) has accepted for standard review a supplemental Biologics License Application (sBLA) for GARDASIL (Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine). The sBLA includes data on protection against vaginal and vulvar cancer caused by HPV types 16 and 18 and data on immune memory. Under the Prescription Drug User Fee Act (PDUFA), for standard sBLAs filed in 2007, the FDA's goal is to review and act on 90 percent of sBLAs within 10 months of receipt. Merck anticipates action by the FDA in the first quarter of 2008.
Cross protection data were also included in this sBLA. These...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Bird Flu
Experts predict Tamiflu could halve the pandemic influenza death toll versus no intervention - Drug Development
FDA Clears 'Computerized Medication Box' for U.S. Market - Epidemic
Curbing the obesity epidemic - Fibromyalgia
FDA Approves First Drug for Treating Fibromyalgia - HIV/AIDS
Drug warning prompts treatment changes for those infected with hepatitis B and HIV - HIV/AIDS
Male circumcision overstated as prevention tool against AIDS - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
